Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, baricitinib (an inhibitor of Janus kinases 1 and 2 (JAK1/JAK2) downstream of IFNγR/IL6R) completely prevented GvHD; expanded regulatory T cells by preserving JAK3-STAT5 signaling; downregulated CXCR3 and helper T cells 1 and 2 while preserving allogeneic antigen-presenting cell-stimulated T-cell proliferation; and suppressed the expression of major histocompatibility complex II (I-Ad), CD80/86, and PD-L1 on host antigen-presenting cells.
|
29691471 |
2018 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease.
|
28665482 |
2017 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the dynamics of IL-8 and IFN-γ in GVHD patients after PTCy was different from previously reported after conventional prophylaxis.
|
28898706 |
2017 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, allogeneic Th1 CD4(+) cells generated during GVHD traffic to hematopoietic sites and induce bone marrow failure via IFNγ-mediated toxicity.
|
23523972 |
2013 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17.
|
22077062 |
2012 |
Graft-vs-Host Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Rosiglitazone inhibited GVHD-induced increases in serum levels of tumor necrosis factor-alpha, interferon-gamma, interleukin (IL)-6, and IL-12, and the GVHD-induced decreases in transforming growth factor-beta and IL-10.
|
22982856 |
2012 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Proinflammatory cytokines released by host tissues during conditioning treatment and interferon gamma released from donor T cells play a major role in acute graft-versus-host disease (GVHD).
|
12394168 |
2002 |
Graft-vs-Host Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The ability of PBMCs to lyse autologous PHA-blasts and T47D tumor cells exhibited an identical temporal relationship with expression of IL-10 and IFN-gamma during autologous GVHD.
|
12239181 |
2002 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
LHGDN |
Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD.
|
12239181 |
2002 |
Graft-vs-Host Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation.
|
11520812 |
2001 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the current study, we used reverse transcription (RT) polymerase chain reaction (PCR) to explore the mRNA expression of candidate inflammatory cytokines IL-1 alpha, IL-2, IL-4, IL-6, TNF-alpha, and interferon-gamma (IFN-gamma) in peripheral blood mononuclear cells (PBMC) and skin biopsies of allogeneic BMT patients with GVHD and controls.
|
7652763 |
1995 |
Graft-vs-Host Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IL-2 expression was not detected at all and interferon-gamma expression was not much changed during GVHD.
|
8136279 |
1993 |